Feature | September 22, 2014

VADs Gaining Popularity, But Artificial Hearts Remain the Ideal, Says GlobalData Analyst

Despite reimbursement limitations prohibiting significant sales, ‘patients considering replacement pumps often have no alternatives

VADs Gain Popularity Artificial Hearts Remain Ideal GlobalData

September 22, 2014 — Robert Littlefield, MSc, GlobalData's senior analyst covering Medical Devices, said:

“Since the first implantation of the Jarvik 7 in 1982, artificial heart devices have evolved significantly in size, design and power usage, but many problems related to sealing, mechanical function, electrical sensing and reliability still persist. While newer devices, such as the Carmat pump, which was recently implanted into a second patient in France, utilize next-generation proprietary membrane materials and advanced motors, many of the same faults regarding longevity and durability continue to plague these products.

“Although several large market players have developed devices, including the Abiomed AbioCor and the Syncardia Total Artificial Heart, reimbursement limitations have prohibited significant sales. However, given the lack of available heart transplants, patients considering replacement pumps often have no alternatives. As a result, and despite the setbacks and low cost-effectiveness of these devices, GlobalData expects that this market will continue to grow from roughly $27 million in 2013 to more than $67 million by 2020, at a Compound Annual Growth Rate (CAGR) of 13%.

“As total artificial hearts only fit in around 20 percent of women and even fewer children, we also foresee a future for other cardiac assist devices that aid, but do not replace, the heart’s function. Ventricular assist devices (VADs), including the Thoratec HeartMate II and the Abiomed Impella, are much smaller than artificial hearts, and can therefore be implanted in a broader set of patients.

“Clinical studies have shown that VAD implantation earlier in a patient’s heart failure progression can slow the deterioration of the condition. Some new heart pump devices, including the Sunshine Heart C-Pulse, have even exhibited an ability to reverse heart failure, which is a very attractive feature for younger patients.

“Given the limited options currently available for advanced heart failure treatment, and the substantial population suitable for VAD implantation earlier in disease progression, GlobalData expects to see continued interest in total artificial hearts, along with considerable adoption of VADs by 2016.”

For more information: www.globaldata.com 

Related Content

News | Ventricular Assist Devices (VAD)

October 20, 2021 – CorWave, a French medtech company developing a next-generation heart pump, won the 2021 HealthTech ...

Home October 20, 2021
Home
Feature | Ventricular Assist Devices (VAD) | By Dave Fornell, Editor

Medtronic announced in June it was stopping the sale and distribution of the Medtronic Heartware HVAD left ventricular ...

Home July 08, 2021
Home
Videos | Ventricular Assist Devices (VAD)

Surgeons at Penn State Heart and Vascular Institute were the second group in the nation to implant a newly-designed ...

Home March 22, 2021
Home
News | Ventricular Assist Devices (VAD)

March 1, 2021 — Medtronic is recalling the HeartWare Ventricular Assist Device (HVAD) Pump Implant Kit because the left ...

Home March 01, 2021
Home
News | Ventricular Assist Devices (VAD)

May 29, 2020 — Medtronic is recalling its HeartWare HVAD left ventricular assist device (LVAD) pump outflow graft and ...

Home May 29, 2020
Home
News | Ventricular Assist Devices (VAD)

January 7, 2020 — Abbott announced U.S. Food and Drug Administration (FDA) approval of a new alternative surgical ...

Home January 07, 2020
Home
Technology | Ventricular Assist Devices (VAD)

September 27, 2019 — Abiomed’s newest heart pump, the Impella 5.5 with SmartAssist, has received U.S. Food and Drug ...

Home September 27, 2019
Home
News | Ventricular Assist Devices (VAD)

September 12, 2019 — CorWave announced successful completion of its first 60-day preclinical study to evaluate its ...

Home September 12, 2019
Home
News | Ventricular Assist Devices (VAD)

August 20, 2019 — Left ventricular assist devices (LVADs) have been shown to help leaky mitral valves that create ...

Home August 20, 2019
Home
News | Ventricular Assist Devices (VAD)

June 12, 2019 — In a letter sent to healthcare providers, the U.S. Food and Drug Administration (FDA) validates that ...

Home June 12, 2019
Home
Subscribe Now